Pieris Pharmaceuticals Inc

NASDAQ:PIRS   3:59:52 PM EDT
4.41
+0.09 (+2.08%)
Debt Financing / Related

Pieris Pharmaceuticals & Astrazeneca AB Entered Into Amendment No. 1 To Non-Exclusive Anticalin Platform License Agreement

Published: 03/30/2021 11:31 GMT
Pieris Pharmaceuticals Inc (PIRS) - Pieris Pharmaceuticals - Co & Astrazeneca Ab Entered Into Amendment No. 1 to Non-exclusive Anticalin Platform License Agreement Dated May 2, 2017.
Pieris Pharmaceuticals Inc - on March 29, Co & Astrazeneca Ab Entered Into Amendment No. 2 to License and Collaboration Agreement Dated May 2, 2017.
Pieris Pharmaceuticals - Parties Agreed to Restructure Some Commercial Economics for Azd1402/prs-060 Program by Adjusting Many Milestones, Royalty Provisions.
Pieris Pharmaceuticals Inc - in Connection With Amended Collaboration Agreement, Co & Astrazeneca Entered Into a Subscription Agreement.
Pieris Pharmaceuticals - Under Subscription Agreement Co Agreed to Issue to Astrazeneca 3.6 Million Shares of Co's Common Stock for $10 Million Or $2.79/share.